Incyte (INCY) Common Equity (2010 - 2026)
Incyte's (INCY) quarterly Common Equity came in at $6.3 billion in Q2 2026, up 52.11% YoY from $4.2 billion in Q2 2025, and up 12.83% on a QoQ basis from $5.6 billion in Q1 2026.
Incyte (INCY) Common Equity (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Common Equity data on file, last reported at $6.3 billion in Q2 2026.
- Quarterly Common Equity rose 52.11% year-over-year to $6.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $6.3 billion (up 52.11% YoY) and the FY2025 annual result came in at $5.2 billion, up 49.89% from the prior year.
- Common Equity advanced to $6.3 billion in Q2 2026, from $5.6 billion in the prior quarter.
- In the past five years, Common Equity ranged from a high of $6.3 billion in Q2 2026 to a low of $3.0 billion in Q2 2024.
- A 5-year average of $4.5 billion and a median of $4.4 billion in 2022 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity slumped 36.78% — and 2026, when it surged 53.31%.
- Tracing INCY's Common Equity over 5 years: stood at $4.4 billion in 2022, then rose by 18.76% to $5.2 billion in 2023, then sank by 33.57% to $3.4 billion in 2024, then surged by 49.89% to $5.2 billion in 2025, then gained by 22.78% to $6.3 billion in 2026.
- The last three Common Equity figures came in at $6.3 billion (Q2 2026), $5.6 billion (Q1 2026), and $5.2 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 6.34 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.34 Bn |
| Mar 31, 2026 | 5.62 Bn |
| Dec 31, 2025 | 5.17 Bn |
| Sep 30, 2025 | 4.65 Bn |
| Jun 30, 2025 | 4.17 Bn |
| Mar 31, 2025 | 3.67 Bn |
| Dec 31, 2024 | 3.45 Bn |
| Sep 30, 2024 | 3.17 Bn |
| Jun 30, 2024 | 3.00 Bn |
| Mar 31, 2024 | 5.39 Bn |
| Dec 31, 2023 | 5.19 Bn |
| Sep 30, 2023 | 4.93 Bn |
| Jun 30, 2023 | 4.74 Bn |
| Mar 31, 2023 | 4.46 Bn |
| Dec 31, 2022 | 4.37 Bn |
| Sep 30, 2022 | 4.23 Bn |
| Jun 30, 2022 | 4.09 Bn |
| Mar 31, 2022 | 3.86 Bn |
| Dec 31, 2021 | 3.77 Bn |
| Sep 30, 2021 | 3.15 Bn |